The adequacy of pharmaceutical treatment of schizophrenia in Quebec varies with age, but is not influenced by sex or neighbourhood deprivation

Canadian Journal of Psychiatry

Volumn 58, Issue 8, 2013, Pages 456-465

  Brouwers, Frederieke M ^a   Courteau, Josiane ^b   Grégoire, Jean Pierre ^c,d   Moisan, Jocelyne ^c,d   Lauzier, Sophie ^c,d   Lesage, Alain ^e   Fleury, Marie Josée ^f,g   Vanasse, Alain ^b,h  

^a UNIVERSITY OF SHERBROOKE   (Canada)

^b Centre Hospitalier Universitaire de Sherbrooke   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

^d LAVAL UNIVERSITY   (Canada)

^e CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

^f MCGILL UNIVERSITY   (Canada)

^g UNIVERSITÉ DE MONTRÉAL   (Canada)

^h UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

Administrative databases; Deprivation; Pharmaceutical management; Population; Schizophrenia

Indexed keywords

ADULT; ARTICLE; CANADA; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NEIGHBORHOOD; PRESCRIPTION; PSYCHIATRIC TREATMENT; RETROSPECTIVE STUDY; SCHIZOPHRENIA;

EID: 84881428084     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674371305800804     Document Type: Article

References (43)

1. Mathers C, Fat DM, Boerma JT; World Health Organization (WHO). The global burden of disease: 2004 update. Geneva (CH): WHO; 2008.
2. Vanasse A, Courteau J, Fleury MJ, et al. Treatment prevalence and incidence of schizophrenia in Quebec using a population health services perspective: different algorithms, different estimates. Soc Psychiatry Psychiatr Epidemiol. 2012;47(4):533-543.
3. Hardeman SM, Harding RK, Narasimhan M. Simplifying adherence in schizophrenia. Psychiatr Serv. 2010;61(4):405-408.
4. Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):71-93.
5. National Collaborating Centre for Mental Health (Great Britain), National Institute for Health and Clinical Excellence (NICE). Schizophrenia core interventions in the treatment and management of schizophrenia in primary and secondary care (update). NICE clinical guidelines no 82. London (GB): NICE; 2009.
6. Ascher-Svanum H, Zhu B, Faries D, et al. A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia. J Clin Psychiatry. 2006;67(7):1114-1123.
7. Weiden PJ, Kozma C, Grogg A, et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004;55(8):886-891.
8. Dunayevich E, Ascher-Svanum H, Zhao F, et al. Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder. J Clin Psychiatry. 2007;68(8):1163-1171.
9. Liu-Seifert H, Adams DH, Kinon BJ. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med. 2005;3:21.
10. Haro JM, Novick D, Suarez D, et al. Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study. J Psychiatr Res. 2009;43(3):265-273.
11. Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085-1097.
12. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223.
13. McEvoy JP, Lieberman JA, Perkins DO, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164(7):1050-1060.
14. Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892-909.
15. Agius M, Davis A, Gilhooley M, et al. What do large scale studies of medication in schizophrenia add to our management strategies? Psychiatr Danub. 2010;22(2):323-328.
16. Zarin DA, Young JL, West JC. Challenges to evidence-based medicine: a comparison of patients and treatments in randomized controlled trials with patients and treatments in a practice research network. Soc Psychiatry Psychiatr Epidemiol. 2005;40(1):27-35.
17. Ahn J, McCombs JS, Jung C, et al. Classifying patients by antipsychotic adherence patterns using latent class analysis: characteristics of nonadherent groups in the California Medicaid (Medi-Cal) program. Value Health. 2008;11(1):48-56.
18. Cooper D, Moisan J, Gregoire JP. Adherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophrenia. J Clin Psychiatry. 2007;68(6):818-825.
19. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry. 2004;161(4):692-699.
20. Valenstein M, Ganoczy D, McCarthy JF, et al. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry. 2006;67(10):1542-1550.
21. Martikainen P, Kauppinen TM, Valkonen T. Effects of the characteristics of neighbourhoods and the characteristics of people on cause specific mortality: a register based follow up study of 252,000 men. J Epidemiol Community Health. 2003;57(3):210-217.
22. Sundquist K, Ahlen H. Neighbourhood income and mental health: a multilevel follow-up study of psychiatric hospital admissions among 4.5 million women and men. Health Place. 2006;12(4):594-602.
23. Boydell J, van Os J, McKenzie K, et al. The association of inequality with the incidence of schizophrenia. Soc Psychiatry Psychiatr Epidemiol. 2004;39(8):597-599.
24. van Os J, Driessen G, Gunther N, et al. Neighbourhood variation in incidence of schizophrenia. Evidence for person-environment interaction. Br J Psychiatry. 2000;176:243-248.
25. Kirkbride JB, Lunn DJ, Morgan C, et al. Examining evidence for neighbourhood variation in the duration of untreated psychosis. Health Place. 2010;16(2):219-225.
26. Crump C, Sundquist K, Sundquist J, et al. Neighborhood deprivation and psychiatric medication prescription: a Swedish national multilevel study. Ann Epidemiol. 2011;21(4):231-237.
27. Kisely S, Smith M, Lawrence D, et al. Inequitable access for mentally ill patients to some medically necessary procedures. CMAJ. 2007;176(6):779-784.
28. Dassa D, Boyer L, Benoit M, et al. Factors associated with medication non-adherence in patients suffering from schizophrenia: a cross-sectional study in a universal coverage health-care system. Aust N Z J Psychiatry. 2010;44(10):921-928.
29. Tamblyn R, Lavoie G, Petrella L, et al. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol. 1995;48(8):999-1009.
30. Karve S, Cleves MA, Helm M, et al. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin. 2009;25(9):2303-2310.
31. Pampalon R, Raymond G. A deprivation index for health and welfare planning in Quebec. Chronic Dis Can. 2000;21(3):104-113.
32. Pampalon R, Hamel D, Gamache P, et al. A deprivation index for health planning in Canada. Chronic Dis Can. 2009;29(4):178-191.
33. Byerly MJ, Nakonezny PA, Lescouflair E. Antipsychotic medication adherence in schizophrenia. Psychiatr Clin North Am. 2007;30(3):437-452.
34. Crumlish N, Whitty P, Clarke M, et al. Beyond the critical period: longitudinal study of 8-year outcome in first-episode non-affective psychosis. Br J Psychiatry. 2009;194(1):18-24.
35. Edlund MJ, Wang PS, Berglund PA, et al. Dropping out of mental health treatment: patterns and predictors among epidemiological survey respondents in the United States and Ontario. Am J Psychiatry. 2002;159(5):845-851.
36. Mullins CD, Obeidat NA, Cuffel BJ, et al. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia. Schizophr Res. 2008;98(1-3):8-15.
37. Addington D, McKenzie E, Smith H, et al. Conformance to evidence-based treatment recommendations in schizophrenia treatment services. Can J Psychiatry. 2012;57(5):317-323.
38. Villeneuve K, Potvin S, Lesage A, et al. Meta-analysis of rates of drop-out from psychosocial treatment among persons with schizophrenia spectrum disorder. Schizophr Res. 2010;121(1-3):266-270.
39. Grymonpre RE, Didur CD, Montgomery PR, et al. Pill count, selfreport, and pharmacy claims data to measure medication adherence in the elderly. Ann Pharmacother. 1998;32(7-8):749-754.
40. Martin BC, Wiley-Exley EK, Richards S, et al. Contrasting measures of adherence with simple drug use, medication switching, and therapeutic duplication. Ann Pharmacother. 2009;43(1):36-44.
41. Jaaskelainen E, Juola P, Hirvonen N, et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull. 2012 Nov 20; Epub ahead of print.
42. Abdel-Baki A, Lesage A, Nicole L, et al. Schizophrenia, an illness with bad outcome: myth or reality? Can J Psychiatry. 2011;56(2):92-101.
43. Alvarez-Jimenez M, Parker AG, Hetrick SE, et al. Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis. Schizophr Bull. 2011;37(3):619-630.